SCHEMBL12378099

SCHEMBL12378099

CC1CCC(C)N1CCS(=O)(=O)N(C)c1c2c(c(O)c3ncccc13)C(=O)N(Cc1ccc(F)cc1)C2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.36
CNR1 P21554 1/20 0.36
COMT P21964 5/20 0.35
PTGDR2 Q9Y5Y4 5/20 0.35
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.35
HSP90AA1 P07900 1/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
PTGDR Q13258 3/20 0.34
KAT2B Q92831 1/20 0.33
TACR1 P25103 1/20 0.32
ENPP2 Q13822 1/20 0.32
CFTR P13569 1/20 0.32
CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4693189 0.88 COMT (0.38) CNR2CNR1COMTPTGDR2KDM4E
SCHEMBL12378084 0.88 KDM4E (0.38) CNR2CNR1COMTPTGDR2KDM4E
SCHEMBL13592664 0.88 CNR2 (0.35) CNR2CNR1COMTPTGDR2KDM4E
SCHEMBL5647896 0.88 METAP2 (0.39) COMTKDM4ELMNAHSP90AA1MAPT
SCHEMBL12378132 0.87 MAPT (0.40) COMTKDM4ELMNAHSP90AA1MAPT
SCHEMBL4696056 0.87 COMT (0.37) CNR2CNR1COMTPTGDR2KDM4E
SCHEMBL5648708 0.87 COMT (0.37) CNR2CNR1COMTPTGDR2KDM4E
SCHEMBL4693839 0.86 METAP2 (0.40) COMTKDM4ELMNAHSP90AA1MAPT
SCHEMBL4693671 0.86 KDM4E (0.37) CNR2COMTKDM4ELMNAHSP90AA1
SCHEMBL4652222 0.86 KDM4E (0.39) CNR2CNR1COMTPTGDR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008287-B2 Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one GILEAD SCIENCES, INC. (US) 2011-08-30 US disclosed
US-8008287-B2 Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one GILEAD SCIENCES, INC. (US) 2011-08-30 US disclosed
US-20090306054-A1 INTEGRASE INHIBITORS GILEAD SCIENCES ,INC. (US) 2009-12-10 US disclosed
US-20090306054-A1 INTEGRASE INHIBITORS GILEAD SCIENCES ,INC. (US) 2009-12-10 US disclosed
US-20080058315-A1 Integrase inhibitors GILEAD SCIENCES, INC. 2008-03-06 US disclosed
US-20080058315-A1 Integrase inhibitors GILEAD SCIENCES, INC. 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058315-A1 Integrase inhibitors TYMP, DNTT, PAICS CNR2 4717/4885CNR1 4630/4885COMT 719/4885
US-20090306054-A1 INTEGRASE INHIBITORS TYMP, POLR2E, CCNI CNR2 4794/4885CNR1 4703/4885COMT 853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.